Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Completed · Phase 1

Conditions studied: CD19 Expressing Malignancies, Hematologic Malignancy

In brief

This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.

Key facts

Study ID

NCT04649112

Run by

Precision BioSciences, Inc.

People needed

13

Starts

2021-06-16

Expected to finish

2023-09-30

Last updated by the study team

2024-07-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory CD19+ expressing malignancies
• At least 2 prior regimens per Standard of Care

You may not qualify if…

• No history of active CNS involvement

Where it is running

• Banner MDA — Gilbert, Arizona, United States
• City of Hope — Duarte, California, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Columbia University — New York, New York, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Lifespan Cancer Institute at Rhode Island Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.